Consent Decree

Regulatory Event

On May 24, 2010, the Department of Justice (DOJ), at the request of the Food and Drug Administration (FDA), filed a consent decree of permanent injunction against Genzyme Corporation and three of its named executives — Chief Executive Officer (CEO) Henri A. Termeer, Senior Vice President for Manufacturing Sciences and Technical Operations W. Blair Okita, and Senior Vice President for Global Product Quality Ronald Branning — in the U.S. District Court for the District of Massachusetts. No new pharmaceutical consent decree action was identified in FDA’s or DOJ’s public enforcement record during this reporting window (the period since XGene’s July 27, 2026 review), so this article revisits Genzyme sixteen years later, not as breaking news but because it remains the clearest case study in how FDA structures a consent decree when the company under enforcement is also the sole source of an irreplaceable therapy. The decree covered Genzyme’s Allston Landing manufacturing facility at 500 Soldiers Field Road, Allston, Massachusetts, and its Current Good Manufacturing Practice (CGMP) basis was a systemic sterile-manufacturing and quality-systems failure, not a data integrity or falsification finding — a distinction that shaped everything about how the decree was written.

The enforcement history behind the decree follows a familiar escalation path with one unusual twist. FDA inspected the Allston facility from September 15 to October 10, 2008, and issued a Warning Letter on February 27, 2009, citing significant CGMP deviations in the manufacture of Fabrazyme, Cerezyme, and Myozyme, including inadequate microbiological contamination controls and deficient air-flow and environmental monitoring. Rather than the case resolving through corrective action, it got materially worse: in June 2009, Genzyme identified Vesivirus 2117 contamination in a 2,000-liter bioreactor used to produce bulk drug substance at Allston, forcing a shutdown across the facility’s bioreactor train and triggering a nationwide shortage of Cerezyme and Fabrazyme, the two enzyme-replacement therapies for Gaucher disease and Fabry disease that had no FDA-approved substitute for many patients at the time. When FDA re-inspected from October 8 to November 13, 2009, it documented continuing systemic inadequacies on Form FDA-483, including finished sterile injectable products contaminated with metal, fiber, rubber, and glass particles — the finding that led directly to the May 2010 decree.

What the Record Documents

What the decree actually required is more operationally distinctive than a standard shutdown order, and this is the detail General Counsels and Boards evaluating biologics manufacturing risk should study most closely. The decree permanently enjoined Genzyme from manufacturing, processing, or distributing any drug at Allston unless an independent expert certified the facility’s compliance and FDA notified the company in writing — the standard consent decree architecture. But Paragraph 5 of the decree simultaneously granted Genzyme written FDA authorization, effective the day the decree was signed, to continue manufacturing, testing, and distributing Cerezyme, Fabrazyme, Myozyme, and Thyrogen specifically because there was no substitute source for patients dependent on them. Thyrogen distribution was further conditioned on a medical-necessity certification protocol requiring customers to sign a Certificate of Procedures Related to Medical Necessity before receiving product. Genzyme was required to retain an independent expert to review every in-process, bulk, and finished batch production record before distribution during the interim period, assign a full-time on-site quality assurance and quality control monitor for at least twelve months after certification, and submit to independent audits at least semiannually for one year and then annually for four more years after compliance was certified. Liquidated damages of $15,000 per violation per day applied to missed milestones, capped at $15 million annually, and FDA billed Genzyme directly for its own supervision costs at hourly rates specified in the decree itself.

The commercial mechanism attached to the decree is unusual enough to warrant its own explanation. Genzyme agreed to pay the U.S. Treasury $175,000,000 in “equitable disgorgement” within fifteen days of entry — profits the government determined the company earned from non-compliant Allston production. The decree explicitly states, at Paragraph 30, that this payment is “not a fine, penalty, forfeiture, or payment in lieu thereof,” a legal distinction that separates disgorgement from a criminal or civil penalty even though the dollar figure is comparable to one. On top of the $175 million, the decree imposed a contingent penalty of 18.5% of product revenue on any fill/finish operations that remained at Allston past specific transfer deadlines, giving Genzyme a direct financial incentive to relocate manufacturing rather than simply remediate in place. The market absorbed this badly: Genzyme’s share price had already fallen roughly 46% from its July 2008 high by the time the decree was signed, driven by the shortages, the shutdown, and the accumulating regulatory overhang. That weakened valuation is widely credited as a contributing factor in Sanofi-Aventis’s unsolicited approach beginning in July 2010, its hostile tender offer that October, and the eventually negotiated $20.1 billion acquisition completed in April 2011 — after which Termeer, the decree’s named individual defendant and Genzyme’s CEO of more than two decades, stepped down as Chairman, President, and CEO.

Technical and Quality Context

Set against the two most commonly cited comparison cases, Genzyme occupies a distinct middle position. The Hi-Tech Pharmacal decree, entered in 2006 for sterile manufacturing failures at its Amityville, New York facility, used a similar batch-record-review-by-expert mechanism, and the company operated under it for four years before FDA agreed to a modified order. Able Laboratories, at the other extreme, saw its 2005 consent decree end in the company’s closure because the cost of compliance exceeded its ability to keep operating. Genzyme’s decree is different from both in the specific way it was engineered: because Cerezyme, Fabrazyme, Myozyme, and Thyrogen had no substitute therapy for many patients, FDA did not simply weigh compliance against continued operation — it built patient-access carve-outs directly into the injunction’s operative paragraphs, conditioned on batch-by-batch expert review rather than a blanket production halt. That is a meaningfully different enforcement posture than either the PharMEDium sterile-compounding case or the Ranbaxy data integrity case already covered in this series: Genzyme shows FDA using the same legal instrument, the consent decree of permanent injunction, to force systemic quality remediation at a company FDA could not afford to let ship product unsupervised, but also could not afford to shut down outright.

The lesson for any single-source or limited-source biologics manufacturer, and for the General Counsel or Board pricing that risk, is that a consent decree is not a fixed choice between “keep operating” and “stop operating.” FDA has demonstrated, in this case, a willingness to write conditional, batch-level authorization into the decree itself when patient dependency is severe enough — but that authorization comes bundled with continuous expert oversight, disgorgement of prior profits, and a revenue-linked penalty structure that makes delay in fixing the underlying problem progressively more expensive. No FDA-published notice of a formal lifting or termination of the Genzyme decree could be located in this review; the decree’s own Paragraph 31 requires 60 months of continuous, certified compliance before Genzyme could even petition the court for relief, and this compilation could not independently confirm what happened after that eligibility window opened. That gap is worth stating plainly rather than assuming a resolution that has not been publicly documented.

Decision Relevance

XGene Consulting supports quality, regulatory, and legal teams navigating exactly this kind of enforcement exposure: consent decree readiness assessment ahead of DOJ/FDA negotiation, Warning Letter and Form 483 remediation built around root-cause correction rather than a paper Corrective and Preventive Action (CAPA) response, process validation remediation for Stage 2 and Stage 3 documentation gaps, and third-party expert support, including the technical documentation an independent expert or auditor will require to certify compliance under decree terms. For biologics and sterile-injectable manufacturers in particular, where a single facility can be the only source of a therapy patients cannot get elsewhere, the Genzyme case is the clearest illustration on record of how FDA balances enforcement against continuity of care — and why the quality system, not the legal negotiation, is what ultimately determines which outcome a company gets.